CN107951006A - 一种具有减肥功能的组合物及其制备方法和用途 - Google Patents
一种具有减肥功能的组合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN107951006A CN107951006A CN201610896755.3A CN201610896755A CN107951006A CN 107951006 A CN107951006 A CN 107951006A CN 201610896755 A CN201610896755 A CN 201610896755A CN 107951006 A CN107951006 A CN 107951006A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- weight
- antierythrite
- buckwheat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 109
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 55
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 44
- 235000019710 soybean protein Nutrition 0.000 claims abstract description 44
- 235000007340 Hordeum vulgare Nutrition 0.000 claims abstract description 43
- 229920002752 Konjac Polymers 0.000 claims abstract description 42
- 244000075850 Avena orientalis Species 0.000 claims abstract description 40
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims abstract description 40
- 240000008620 Fagopyrum esculentum Species 0.000 claims abstract description 40
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims abstract description 40
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 40
- 235000007199 Panicum miliaceum Nutrition 0.000 claims abstract description 40
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims abstract description 40
- 235000012054 meals Nutrition 0.000 claims abstract description 40
- 235000007319 Avena orientalis Nutrition 0.000 claims abstract description 39
- 235000013312 flour Nutrition 0.000 claims abstract description 39
- 229920001202 Inulin Polymers 0.000 claims abstract description 38
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 38
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 38
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 38
- 229940029339 inulin Drugs 0.000 claims abstract description 38
- 239000010985 leather Substances 0.000 claims abstract description 38
- 239000003094 microcapsule Substances 0.000 claims abstract description 38
- 239000012141 concentrate Substances 0.000 claims abstract description 36
- 235000021388 linseed oil Nutrition 0.000 claims abstract description 36
- 239000000944 linseed oil Substances 0.000 claims abstract description 36
- 235000021119 whey protein Nutrition 0.000 claims abstract description 36
- 239000002994 raw material Substances 0.000 claims abstract description 25
- 239000000463 material Substances 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 21
- 235000013305 food Nutrition 0.000 claims abstract description 16
- 230000036541 health Effects 0.000 claims abstract description 15
- 230000008569 process Effects 0.000 claims abstract description 4
- 240000005979 Hordeum vulgare Species 0.000 claims abstract 6
- 244000022185 broomcorn panic Species 0.000 claims abstract 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 238000007873 sieving Methods 0.000 claims description 12
- 208000008589 Obesity Diseases 0.000 claims description 10
- 235000020824 obesity Nutrition 0.000 claims description 9
- 239000000377 silicon dioxide Substances 0.000 claims description 9
- 206010020772 Hypertension Diseases 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- 244000269722 Thea sinensis Species 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 235000013616 tea Nutrition 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000000287 crude extract Substances 0.000 claims description 6
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- 229920002401 polyacrylamide Polymers 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000004440 column chromatography Methods 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- 230000001631 hypertensive effect Effects 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 238000001256 steam distillation Methods 0.000 claims description 4
- 238000003809 water extraction Methods 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 238000007670 refining Methods 0.000 claims description 3
- 235000015091 medicinal tea Nutrition 0.000 claims description 2
- 240000006240 Linum usitatissimum Species 0.000 claims 2
- 235000004431 Linum usitatissimum Nutrition 0.000 claims 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 1
- 235000007516 Chrysanthemum Nutrition 0.000 claims 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 239000003595 mist Substances 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 abstract description 5
- 230000035764 nutrition Effects 0.000 abstract description 5
- 239000002131 composite material Substances 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 241000209219 Hordeum Species 0.000 description 38
- 244000022203 blackseeded proso millet Species 0.000 description 34
- 235000008504 concentrate Nutrition 0.000 description 30
- 235000019197 fats Nutrition 0.000 description 16
- 235000009508 confectionery Nutrition 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- -1 flavouring Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 235000020985 whole grains Nutrition 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 235000013339 cereals Nutrition 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 125000005456 glyceride group Chemical group 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000000811 xylitol Substances 0.000 description 4
- 235000010447 xylitol Nutrition 0.000 description 4
- 229960002675 xylitol Drugs 0.000 description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 4
- 108010011485 Aspartame Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 229960002737 fructose Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000000050 nutritive effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 108700022737 rat Fat1 Proteins 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 235000016068 Berberis vulgaris Nutrition 0.000 description 2
- 241000335053 Beta vulgaris Species 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 241000206575 Chondrus crispus Species 0.000 description 2
- 244000077995 Coix lacryma jobi Species 0.000 description 2
- MKMCJLMBVKHUMS-UHFFFAOYSA-N Coixol Chemical compound COC1=CC=C2NC(=O)OC2=C1 MKMCJLMBVKHUMS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004407 Lactalbumin Human genes 0.000 description 2
- 108090000942 Lactalbumin Proteins 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 235000021120 animal protein Nutrition 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 235000004213 low-fat Nutrition 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 235000014380 magnesium carbonate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 235000005781 Avena Nutrition 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 201000001498 Froelich syndrome Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 108010073032 Grain Proteins Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 241000209117 Panicum Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 208000007683 Pediatric Obesity Diseases 0.000 description 1
- 101710089165 Protein white Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 231100000784 hepatotoxin Toxicity 0.000 description 1
- 239000008123 high-intensity sweetener Substances 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种具有减肥功能的组合物,同时还公开了所述组合物的制备方法和用途。所述组合物原料为青稞,荞麦,薏仁米,燕麦,带皮糜子、大豆粉、亚麻籽油微囊粉、浓缩乳清蛋白、大豆分离蛋白、低聚果糖、菊粉、赤藓糖醇、魔芋粉。本发明既满足基本营养物质和热量需求,又可以最大限度的降低能量摄入值从而达到减肥的目的,可广泛用于制备食品或保健品;同时所述组合物制备方法简单,工艺流程稳定,且原料易得,适于规模化生产。
Description
技术领域
本发明属于食品或保健品领域,特别涉及一种具有减肥功能的组合物及其制备方法和用途。
背景技术
肥胖是指一定程度的明显超重与脂肪层过厚,是体内脂肪,尤其是甘油三酯积聚过多而导致的一种状态。由于食物摄入过多或机体代谢的改变而导致体内脂肪积聚过多造成体重过度增长并引起人体病理、生理改变或潜伏。目前,世界卫生组织已将肥胖定为疾病,是继心脑血管病和癌症之后对人类健康威胁的第三大杀手。肥胖易引发高血压、冠心病、脂肪肝、糖尿病、高血脂、痛风及胆石症等多种疾病。单纯性肥胖患者通过临床化验,绝大多数患者出现内分泌紊乱,尤其是高胰岛素血症、糖耐量实验异常、性激素水平紊乱、肾上腺皮质激素偏高、瘦素增高等等,青少年肥胖还易导致肥胖性生殖无能症。
对于肥胖的治疗,主要集中在两个环节上:减少热量摄取和增加热量消耗。一般以行为、饮食、运动为主的综合治疗,必要时辅以药物或手术治疗。继发性肥胖症应针对病因进行治疗。各种并发症及伴随病应给予相应的处理。
1.行为治疗。通过宣传教育使患者及其家属对肥胖症及其危害性有正确的认识,从而配合治疗、采取健康的生活方式、改变饮食和运动习惯。自觉地长期坚持是肥胖症治疗首位及最重要的措施。
2.控制饮食及增加体力活动。轻度肥胖者,控制进食总量,采用低热卡、低脂肪饮食,避免摄入高糖高脂类食物,使每日总热量低于消耗量。多作体力劳动和体育锻炼,如能使体重每月减轻500~1000g而渐渐达到正常标准体重,则不必用药物治疗。关于活动量或运动量的制定应该因人而异,原则上采取循序渐进的方式。
3.药物治疗。对严重肥胖患者可应用药物减轻体重,然后继续维持。但临床上如何更好地应用这类药物仍有待探讨。用药可能产生药物副作用及耐药性,因而选择药物治疗的适应证必须十分慎重,根据患者的个体情况衡量可能得到的益处和潜在的危险作出决定。
4.外科治疗。空回肠短路手术、胆管胰腺短路手术、胃短路手术、胃成形术、迷走神经切断术及胃气囊术等,可供选择。手术有效(指体重降低>20%)率可达95%,死亡率<1%。不少患者可获得长期疗效,术前并发症可不同程度地得到改善或治愈。但手术可能并发吸收不良、贫血、管道狭窄等,有一定的危险性,仅用于重度肥胖、减肥失败又有严重并发症,而这些并发症有可能通过体重减轻而改善者。术前要对患者的全身情况作出充分估计,特别是糖尿病、高血压和心肺功能等,给予相应的监测和处理。
综上,对治疗肥胖而言,相对药物治疗的副作用及耐药性和手术的危险性,食疗因其更安全、无毒副作用、物美价廉等优势而使人们更加青睐,因此研制一种具有减肥功能的食品或保健品相当迫切,其市场前景也定会相当广阔。
发明内容
基于上述现状,本发明的目的之一是提供一种具有减肥功能的组合物,通过人体降低摄入能量来达到瘦身减肥的效果,其安全性高,无副作用。
本发明的另一目的是提供一种制备上述组合物的方法。
本发明的又一目的是提供上述组合物的用途。
为实现上述方案,本发明提供了以下技术方案:
所述组合物,由以下重量份配比的原料组成:青稞10-100份,荞麦10-100份,薏仁米10-100份,燕麦100-300份,带皮糜子10-100份、大豆粉100-300份、亚麻籽油微囊粉10-100份、浓缩乳清蛋白1-80份、大豆分离蛋白100-300份、低聚果糖1-100份、菊粉10-100份、赤藓糖醇10-200份、魔芋粉1-80份。
进一步,所述的原料重量份配比为:青稞20-80份,荞麦20-90份,薏仁米30-90份,燕麦30-80份,带皮糜子25-90份、大豆粉125-270份、亚麻籽油微囊粉25-90份、浓缩乳清蛋白5-65份、大豆分离蛋白125-280份、低聚果糖10-85份、菊粉20-80份、赤藓糖醇30-125份、魔芋粉5-65份。
进一步,所述的原料重量份配比为:青稞40-70份,荞麦40-80份,薏仁米40-80份,燕麦45-70份,带皮糜子45-80份、大豆粉165-225份、亚麻籽油微囊粉35-65份、浓缩乳清蛋白10-50份、大豆分离蛋白150-250份、低聚果糖20-60份、菊粉35-70份、赤藓糖醇65-115份、魔芋粉10-40份。
以上各组合物成分来源与功效如下:
青稞:(hullessbarley)是禾本科大麦属的一种禾谷类作物,因其内外颖壳分离,籽粒裸露,故又称裸大麦、元麦、米大麦。藏医典籍《晶珠本草》把青稞米作为一种重要药物,用于治疗多种疾病。据《本草拾遗》记载:青稞米,下气宽中、壮精益力、除湿发汗、止泻。现代医学科学研究发现,青稞米中对人体有益的成分是它成为糖尿病患者、减肥人群、“三高”人群的天然健康食品的基础。
荞麦:(Fagopyrum esculentum Moench.),别名:甜荞、乌麦、三角麦等;一年生草本。其性甘味凉,有开胃宽肠,下气消积,治绞肠痧,肠胃积滞,慢性泄泻的功效。因其含丰富营养和特殊的健康成分颇受推崇,被誉为健康主食品,人们视之为理想的保健食品,尤其是对高血压、冠心病、糖尿病、癌症等有特殊的保健作用。
薏仁米:是薏苡仁的种子,其味甘淡,微寒,各部位都可入药。苡仁油,能兴奋呼吸、使肺血管显著扩张,减少肌肉及末梢神经的挛缩及麻痹;苡仁酯,具有滋补作用,而且还是一种抗癌剂,可抑制艾氏腹水癌细胞,用于治疗胃癌及子宫颈癌;薏苡素,具有解热、镇痛作用;薏苡根,具有滋补、抗癌、降压、解热、利尿、驱虫之功能,适用于高血压、尿路结石、尿路感染、蛔虫病等症;薏苡叶,可煎茶饮,其味清香,饮之可以利尿。
燕麦:(Avena sativaL.)为禾本科植物,性味甘平,属于中国人常食用的9种粮食之一。能益脾养心、敛汗。其富含膳食纤维,分别是小麦和玉米的4.7倍和7.7倍,能促进肠胃蠕动,利于排便,热量低,升糖指数低,降脂降糖,也是高档补品之一。中国医学科学院卫生研究所综合分析,中国裸燕麦含粗蛋白质达15.6%,脂肪8.5%,还有淀粉释放热量以及磷、铁、钙等元素,与其它8种粮食相比,均名列前茅。
带皮糜子:(Panicum miliaceum L)属禾本科黍属,又称黍、稷、禾祭和糜。其性味甘、平、微寒、无毒,养胃健胃、补气益气,同时还有很高的营养价值,蛋白质含量12%左右;淀粉含量70%左右,其中糯性品种为67.6%,粳性品种为72.5%。此外还含有β—胡萝卜素、维生素E、维生素B6、B1、B2等多种维生素和丰富的钙、镁、磷及铁、锌、铜等矿物质元素。
大豆粉:是以脱脂大豆为原料加工而成的豆粉。其具有很高的营养价值,所含蛋白质含量高达40%,是优质蛋白质,含有人体所必需的氨基酸,其中赖氨酸的含量高干谷物,是植物性食物当中最合理、最接近干人体所需比例,近年来,美国和英国先后发布健康声明:每天食用6.25克大豆蛋白,可以预防心血管疾病,使人们更加重视大豆蛋白的保健作用;豆粉中的脂肪主要是植物脂肪,不饱和脂肪酸含量较高,并含有人体所必需脂肪酸亚油酸,胆固醇含量低,可以预防动脉硬化。
亚麻籽油微囊粉:其可通过抑制食欲、加速新陈代谢来促进脂肪的消耗;可降低血液中高胆固醇25%及三酸甘油脂65%,将多余的低密度胆固醇(LDL)转变成胆酸排出体外;可增加吸收能力,增加肠的蠕动能力使排便正常,减少便秘。
浓缩乳清蛋白:在各种蛋白质中,乳清蛋白的营养价值是最高的。它属于优质的完全蛋白质,也是动物性蛋白,含有人体必需的8种氨基酸,且配比合理,接近人体的需求比例,是人体生长、发育、抗衰老等生命活动不可缺少的精华物质,可长期服用。
大豆分离蛋白:大豆分离蛋白中蛋白质含量在90%以上,氨基酸种类有近20种,并含有人体必需氨基酸。其营养丰富,不含胆固醇,是植物蛋白中为数不多的可替代动物蛋白的品种之一。无论对素食主义者还是对普通人,大豆分离蛋白粉都是完美的优质蛋白补充品;对需要低热量膳食的减肥者而言,用大豆蛋白代替膳食中部分蛋白,不仅降低了胆固醇与饱和脂肪的摄入量,同时也达到了营养摄取的均衡;每日服用大豆蛋白亦可有效降低人体血液中总胆固醇和低密度脂蛋白胆固醇的含量,从而降低患心脏病的风险。
低聚果糖:是一种天然活性物质。甜度为蔗糖的0.3-0.6倍。既保持了蔗糖的纯正甜味性质,又比蔗糖甜味清爽。其可调节肠道菌群,增殖双歧杆菌;可促进微量元素铁、钙的吸收与利用;可调节血脂;可减少肝脏毒素,有显著的防癌功能。
菊粉:是植物中储备性多糖,主要来源于植物。其可降低血糖值、淡化血糖的浓度;改善血管障碍,降低胆固醇;还很难或不被人体消化吸收,所提供的能量值很低或根本没有,故可在低能量食品中发挥作用,最大限度的满足了那些喜爱甜品又担心发胖者的需求,还可供高血脂病人、糖尿病人、肥胖病人和低血糖病人食用。
赤藓糖醇:白色结晶,微甜,相对甜度0.65,有清凉感,发热量低,约为蔗糖发热量的十分之一。零热量纯天然生物糖,是所有糖醇类甜味剂中能量最低的一种,特别适合糖尿病患者、肥胖人群高血压病人及心脑血管病人食用。
魔芋粉:是一种根茎植物,是当今发现的、唯一能大量提供葡聚糖的经济作物,在食品医药领域里魔芋的使用价值将不停地被开发展示出来。魔芋的食用价值使它受到人们普遍欢迎,魔芋的主要成份是葡甘露聚糖,它不只含有人体所需的超过10种氨基酸和多种微量元素,也具有低蛋白质、低脂肪高纤维、吸水性好、膨胀率高等特性,药用功效具有降血脂、降血糖、降血压、减肥、美容、保健、通便及等更多效果。
进一步,所述组合物为口服制剂,呈现为粉剂、片剂、胶囊剂、丸剂、颗粒剂、口服液体制剂、袋装茶剂、袋泡茶剂任意一种形式。
进一步,所述组合物是通过以下步骤制备而成:将所述重量份的原料粉碎成粗粉;或加水或不同浓度的乙醇提取,提取液浓缩干燥得粗提物;或进一步采用水提醇沉法、离心法、有机溶剂萃取法、柱层析法、水蒸气蒸馏法进行精制得到精提物;上述药材粗粉或粗提物或精提物不加或者加入适量辅料制成相应剂型。
根据不同的制剂其载体或辅料有所不同,如在片剂、胶囊剂、颗粒剂、粉剂等固体制剂中常用的稀释剂、崩解剂、赋形剂、粘合剂、润滑剂、表面活性剂、填充剂等;在糖浆、口服液等液体制剂形式中常用的表面活性剂、稀释剂、防腐剂、稳定剂、矫味剂、增稠剂等。
其常用辅料如淀粉、乳糖、蔗糖、糊精、糖粉、微晶纤维素、甘露醇、木糖醇、聚乙二醇、硫酸钙、磷酸氢钙、碳酸钙、改良淀粉、山梨醇、赤藓糖醇、聚乙烯吡咯烷酮、重质碳酸镁、羧甲基纤维素钠、羟丙甲基纤维素、甲基纤维素、乙基纤维素、羧甲淀粉钠、羟丙基纤维素、聚维酮K30、白陶土、预胶化淀粉、硬脂酸镁、滑石粉、微粉硅胶、二氧化硅、甜叶菊苷、甜菜碱、阿司帕坦、甘草甜素、糖精钠、冰糖、蜂蜜、三氯蔗糖、木糖醇、枸橼酸、碳酸氢钠、碳酸钠、卡拉胶、琼脂、明胶、海藻酸钠、黄原胶、瓜耳豆胶、西黄耆胶、阿拉伯胶、槐豆胶、硬脂酸、单硬脂酸甘油酯、聚丙烯酰胺、交联型聚丙烯酸钠、聚乙烯醇、卡波姆、山梨酸、山梨酸钾、羟苯乙酯、苯甲醇、尼泊金、硫柳汞、二甲基亚砜、氮酮、三乙醇胺、氢氧化钠、甘油、丙二醇、BHT、BHA、十二烷基硫酸钠、吐温类、司盘类等。
进一步,所述组合物是通过以下步骤制备而成:
1)将青稞、荞麦、薏仁米、燕麦、带皮糜子炒制,粉碎、过筛,制得组合物A,将低聚果糖、菊粉、赤藓糖醇、魔芋粉粉碎过筛制得组合物B;
2)将组合物A、B与大豆粉、亚麻籽油微囊粉、浓缩乳清蛋白、大豆分离蛋白混合,加适量辅料,混合均匀,过筛,即得。
进一步,所述辅料为硬脂酸镁、滑石粉、微粉硅胶、二氧化硅、硬脂酸、单硬脂酸甘油酯、聚丙烯酰胺一种或几种。
根据本发明的另一个目的,提供一种制备上述组合物的方法,包括以下步骤:将所述重量份的原料粉碎成粗粉;或加水或不同浓度的乙醇提取,提取液浓缩干燥得粗提物;或进一步采用水提醇沉法、离心法、有机溶剂萃取法、柱层析法、水蒸气蒸馏法进行精制得到精提物;上述药材粗粉或粗提物或精提物不加或者加入适量辅料制成相应剂型。
根据不同的制剂其载体或辅料有所不同,如在片剂、胶囊剂、颗粒剂等固体制剂中常用的稀释剂、崩解剂、赋形剂、粘合剂、润滑剂、表面活性剂、填充剂等;在糖浆、口服液等液体制剂形式中常用的表面活性剂、稀释剂、防腐剂、稳定剂、矫味剂、增稠剂等。
其常用辅料如淀粉、乳糖、蔗糖、糊精、糖粉、微晶纤维素、甘露醇、木糖醇、聚乙二醇、硫酸钙、磷酸氢钙、碳酸钙、改良淀粉、山梨醇、赤藓糖醇、聚乙烯吡咯烷酮、重质碳酸镁、羧甲基纤维素钠、羟丙甲基纤维素、甲基纤维素、乙基纤维素、羧甲淀粉钠、羟丙基纤维素、聚维酮K30、白陶土、预胶化淀粉、硬脂酸镁、滑石粉、微粉硅胶、二氧化硅、甜叶菊苷、甜菜碱、阿司帕坦、甘草甜素、糖精钠、冰糖、蜂蜜、三氯蔗糖、木糖醇、枸橼酸、碳酸氢钠、碳酸钠、卡拉胶、琼脂、明胶、海藻酸钠、黄原胶、瓜耳豆胶、西黄耆胶、阿拉伯胶、槐豆胶、硬脂酸、单硬脂酸甘油酯、聚丙烯酰胺、交联型聚丙烯酸钠、聚乙烯醇、卡波姆、山梨酸、山梨酸钾、羟苯乙酯、苯甲醇、尼泊金、硫柳汞、二甲基亚砜、氮酮、三乙醇胺、氢氧化钠、甘油、丙二醇、BHT、BHA、十二烷基硫酸钠、吐温类、司盘类等。
进一步,所述方法包括以下步骤:
1)将青稞、荞麦、薏仁米、燕麦、带皮糜子炒制,粉碎、过筛制得组合物A,将低聚果糖、菊粉、赤藓糖醇、魔芋粉粉碎过筛制得组合物B;
2)将组合物A、B与大豆粉、亚麻籽油微囊粉、浓缩乳清蛋白、大豆分离蛋白混合,加适量辅料,混合均匀,过筛,即得。
进一步,所述辅料为硬脂酸镁、滑石粉、微粉硅胶、二氧化硅、硬脂酸、单硬脂酸甘油酯、聚丙烯酰胺一种或几种。
根据本发明的又一目的,提供所述组合物的用途,可作为制备减肥的食品或保健品中的用途。
进一步,所述组合物作为制备供糖尿病人、肥胖性高血压病人和心血管病人食用的食品或保健品中的用途。
本发明的有益效果
本发明组分配方依据中国传统养生理论以及国际控制体重和减轻体重配方食品法典标准,结合现代生物技术手段科学制成。配方中大豆分离蛋白、乳清蛋白为完全蛋白质,含有人体所有必须氨基酸,相比谷类蛋白和豌豆蛋白等不完全蛋白而言,氨基酸组成合理,更适合长期服用。该配方中还使用了零热量生物糖-赤藓糖醇作为甜味剂,口感清新,甜度近似白砂糖,取代化学合成的具有200倍甜度的阿斯巴甜等高甜度甜味剂,同时结合低聚果糖、菊粉、魔芋粉等具有降脂、降糖、减肥功能的低度甜味剂。因此,肥胖人士服用本发明组合物,既满足其身体基本营养物质和热量需求,又可以最大限度的降低能量的摄入。如长期服用,减肥效果更好。由于添加零热量,低甜度的甜味剂,因此也适合糖尿病患者、肥胖人群高血压病人及心脑血管病人服用。
具体实施例
下面结合具体实施方式对本发明的上述发明内容进一步详细描述。
但不应将此理解为本发明上述主题的范围仅限于下述实施例。在不脱离本发明上述技术思想情况下,根据本领域普通技术知识和惯用手段,做出各种替换和变更,均应包括在本发明的范围内。
实施例1青稞60份,荞麦60份,薏仁米60份,燕麦60份,带皮糜子60份、大豆粉200份、亚麻籽油微囊粉50份、浓缩乳清蛋白20份、大豆分离蛋白180份、低聚果糖40份、菊粉60份、赤藓糖醇111份、魔芋粉14份
称取上述重量配比原料,将青稞、荞麦、薏仁米、燕麦、带皮糜子炒制,粉碎、过60目筛制得组合物A,将低聚果糖、菊粉、赤藓糖醇、魔芋粉粉碎过60目筛制得组合物B;将组合物A、B与大豆粉、亚麻籽油微囊粉、浓缩乳清蛋白、大豆分离蛋白混合,加二氧化硅、单硬脂酸甘油酯,混合均匀,过筛,制成粉剂。
实施例2青稞25份,荞麦25份,薏仁米88份,燕麦35份,带皮糜子30份、大豆粉260份、亚麻籽油微囊粉80份、浓缩乳清蛋白6份、大豆分离蛋白275份、低聚果糖13份、菊粉25份、赤藓糖醇35份、魔芋粉7份
称取上述重量配比原料,将青稞、荞麦、薏仁米、燕麦、带皮糜子炒制,粉碎、过60目筛制得组合物A,将低聚果糖、菊粉、赤藓糖醇、魔芋粉粉碎过60目筛制得组合物B;将组合物A、B与大豆粉、亚麻籽油微囊粉、浓缩乳清蛋白、大豆分离蛋白混合,加二氧化硅、单硬脂酸甘油酯,混合均匀,过筛,制成粉剂。
实施例3青稞10份,荞麦100份,薏仁米100份,燕麦10份,带皮糜子100份、大豆粉100份、亚麻籽油微囊粉10份、浓缩乳清蛋白1份、大豆分离蛋白100份、低聚果糖100份、菊粉10份、赤藓糖醇200份、魔芋粉80份
称取上述重量配比原料,将青稞、荞麦、薏仁米、燕麦、带皮糜子炒制,粉碎、过60目筛制得组合物A,将低聚果糖、菊粉、赤藓糖醇、魔芋粉粉碎过60目筛制得组合物B;将组合物A、B与大豆粉、亚麻籽油微囊粉、浓缩乳清蛋白、大豆分离蛋白混合,加二氧化硅、单硬脂酸甘油酯,混合均匀,过筛,制成粉剂。
实施例4青稞12份,荞麦15份,薏仁米95份,燕麦15份,带皮糜子15份、大豆粉285份、亚麻籽油微囊粉95份、浓缩乳清蛋白3份、大豆分离蛋白290份、低聚果糖90份、菊粉90份、赤藓糖醇20份、魔芋粉70份
称取上述重量配比原料,将青稞、荞麦、薏仁米、燕麦、带皮糜子炒制,粉碎、过60目筛制得组合物A,将低聚果糖、菊粉、赤藓糖醇、魔芋粉粉碎过60目筛制得组合物B;将组合物A、B与大豆粉、亚麻籽油微囊粉、浓缩乳清蛋白、大豆分离蛋白混合,加二氧化硅、单硬脂酸甘油酯,混合均匀,过筛,制成粉剂。
实施例5青稞85份,荞麦85份,薏仁米85份,燕麦75份,带皮糜子85份、大豆粉150份、亚麻籽油微囊粉30份、浓缩乳清蛋白60份、大豆分离蛋白130份、低聚果糖80份、菊粉75份、赤藓糖醇165份、魔芋粉50份
称取上述重量配比原料,将青稞、荞麦、薏仁米、燕麦、带皮糜子炒制,粉碎、过60目筛制得组合物A,将低聚果糖、菊粉、赤藓糖醇、魔芋粉粉碎过60目筛制得组合物B;将组合物A、B与大豆粉、亚麻籽油微囊粉、浓缩乳清蛋白、大豆分离蛋白混合,过40目筛,与适量乳糖混匀,制粒,干燥,整粒,加入适量硬脂酸镁,混匀,压片,包衣,制成片剂。
实施例6青稞70份,荞麦80份,薏仁米40份,燕麦70份,带皮糜子45份、大豆粉165份、亚麻籽油微囊粉35份、浓缩乳清蛋白50份、大豆分离蛋白150份、低聚果糖20份、菊粉70份、赤藓糖醇145份、魔芋粉40份
称取上述重量配比原料,将青稞、荞麦、薏仁米、燕麦、带皮糜子炒制,粉碎、过60目筛制得组合物A,将低聚果糖、菊粉、赤藓糖醇、魔芋粉粉碎过60目筛制得组合物B;将组合物A、B与大豆粉、亚麻籽油微囊粉、浓缩乳清蛋白、大豆分离蛋白混合,过40目筛,与适量乳糖混匀,制粒,干燥,整粒,加入适量硬脂酸镁,混匀,压片,包衣,制成片剂。
实施例7青稞50份,荞麦70份,薏仁米70份,燕麦55份,带皮糜子70份、大豆粉180份、亚麻籽油微囊粉40份、浓缩乳清蛋白40份、大豆分离蛋白200份、低聚果糖50份、菊粉50份、赤藓糖醇130份、魔芋粉30份
称取上述重量配比原料,将青稞、荞麦、薏仁米、燕麦、带皮糜子炒制,粉碎、过60目筛制得组合物A,将低聚果糖、菊粉、赤藓糖醇、魔芋粉粉碎过60目筛制得组合物B;将组合物A、B与大豆粉、亚麻籽油微囊粉、浓缩乳清蛋白、大豆分离蛋白混合,过40目筛,与适量甘露醇、微晶纤维素混匀,制粒,干燥,整粒,即得颗粒剂。
实施例8青稞80份,荞麦20份,薏仁米90份,燕麦80份,带皮糜子25份、大豆粉125份、亚麻籽油微囊粉25份、浓缩乳清蛋白65份、大豆分离蛋白280份、低聚果糖85份、菊粉80份、赤藓糖醇30份、魔芋粉5份
称取上述重量配比原料,将青稞、荞麦、薏仁米、燕麦、带皮糜子炒制,粉碎、过60目筛制得组合物A,将低聚果糖、菊粉、赤藓糖醇、魔芋粉粉碎过60目筛制得组合物B;将组合物A、B与大豆粉、亚麻籽油微囊粉、浓缩乳清蛋白、大豆分离蛋白混合,过40目筛,与适量甘露醇、微晶纤维素混匀,制粒,干燥,整粒,即得颗粒剂。
实施例9青稞95份,荞麦95份,薏仁米20份,燕麦90份,带皮糜子95份、大豆粉110份、亚麻籽油微囊粉20份、浓缩乳清蛋白75份、大豆分离蛋白110份、低聚果糖5份、菊粉15份、赤藓糖醇190份、魔芋粉5份
称取上述重量配比原料,将青稞、荞麦、薏仁米、燕麦、带皮糜子炒制,粉碎、过60目筛制得组合物A,将低聚果糖、菊粉、赤藓糖醇、魔芋粉粉碎过60目筛制得组合物B;将组合物A、B与大豆粉、亚麻籽油微囊粉、浓缩乳清蛋白、大豆分离蛋白混合,过40目筛,与适量麦芽糊精、乳糖混匀,制粒,干燥,整粒,装空心硬胶囊,即得硬胶囊剂。
实施例10青稞20份,荞麦90份,薏仁米30份,燕麦30份,带皮糜子90份、大豆粉270份、亚麻籽油微囊粉90份、浓缩乳清蛋白5份、大豆分离蛋白125份、低聚果糖10份、菊粉20份、赤藓糖醇175份、魔芋粉65份
称取上述重量配比原料,将青稞、荞麦、薏仁米、燕麦、带皮糜子炒制,粉碎、过60目筛制得组合物A,将低聚果糖、菊粉、赤藓糖醇、魔芋粉粉碎过60目筛制得组合物B;将组合物A、B与大豆粉、亚麻籽油微囊粉、浓缩乳清蛋白、大豆分离蛋白混合,过40目筛,加入适量辅料,混匀,制成丸剂。
实施例11青稞100份,荞麦10份,薏仁米10份,燕麦100份,带皮糜子10份、大豆粉300份、亚麻籽油微囊粉100份、浓缩乳清蛋白80份、大豆分离蛋白300份、低聚果糖1份、菊粉100份、赤藓糖醇10份、魔芋粉1份
称取上述重量配比原料,将青稞、荞麦、薏仁米、燕麦、带皮糜子炒制,粉碎、过60目筛制得组合物A,将低聚果糖、菊粉、赤藓糖醇、魔芋粉粉碎过60目筛制得组合物B;将组合物A、B与大豆粉、亚麻籽油微囊粉、浓缩乳清蛋白、大豆分离蛋白混合,过40目筛,与适量甘露醇、微晶纤维素混匀,制粒,干燥,整粒,即得颗粒剂。
实施例12青稞40份,荞麦40份,薏仁米80份,燕麦45份,带皮糜子80份、大豆粉225份、亚麻籽油微囊粉65份、浓缩乳清蛋白10份、大豆分离蛋白250份、低聚果糖60份、菊粉35份、赤藓糖醇65份、魔芋粉10份
称取上述重量配比原料,将青稞、荞麦、薏仁米、燕麦、带皮糜子炒制,粉碎、过60目筛制得组合物A,将低聚果糖、菊粉、赤藓糖醇、魔芋粉粉碎过60目筛制得组合物B;将组合物A、B与大豆粉、亚麻籽油微囊粉、浓缩乳清蛋白、大豆分离蛋白混合,过40目筛,与适量甘露醇、微晶纤维素混匀,制粒,干燥,整粒,即得颗粒剂。
实施例13青稞55份,荞麦50份,薏仁米50份,燕麦65份,带皮糜子50份、大豆粉190份、亚麻籽油微囊粉60份、浓缩乳清蛋白30份、大豆分离蛋白220份、低聚果糖30份、菊粉65份、赤藓糖醇120份、魔芋粉20份
称取上述重量配比原料,将青稞、荞麦、薏仁米、燕麦、带皮糜子炒制,粉碎、过60目筛制得组合物A,将低聚果糖、菊粉、赤藓糖醇、魔芋粉粉碎过60目筛制得组合物B;将组合物A、B与大豆粉、亚麻籽油微囊粉、浓缩乳清蛋白、大豆分离蛋白混合,过40目筛,制成袋装茶剂、袋泡茶剂。
通过以下实验进一步阐述本发明所述组合物的有益效果:
1材料和方法
1.1材料
1.1.1样品:实施例1、2、3制备的样品。
1.1.2实验动物:大鼠,200±20g,雄性,SPF级。
1.1.3仪器:动物天平、解剖器械等。
1.1.4营养饲料配方:基础饲料80%、猪油10%、蛋黄粉10%
1.2方法
1.2.1预防肥胖模型法
将50只大鼠随机分为正常对照组、模型对照组及三个受试样品实验组,实验开始时,模型对照组和实验组每日给予等量的营养饲料,正常对照组以相同方式给予基础饲料。饲料给予量与营养饲料相同。实验组1、2、3给予实施例1、2、3制备的样品,正常对照组和模型对照组给予相应溶剂。实验时间6周,实验期间记录给食量、剩食量及撒食量,每周称体重,试验结束时称体重,剖腹取体脂并称重,计算脂/体比。
2、实验结果
2.1本发明组合物对大鼠体重的影响
表1本发明组合物对大鼠体重的影响
*表示与模型对照组比较差异有显著性意义(P<0.05)
**表示与模型对照组比较差异有极显著性意义(P<0.01)
从表1可见,各实验组大鼠体重每周增重均低于模型对照组,实验组1与模型对照组的差异具有极显著意义(P<0.01),实验组2、3与模型对照组的差异具有显著意义(P<0.05)。
2.2本发明组合物对大鼠总摄食量的影响
表2本发明组合物对大鼠总摄食量的影响
*表示与模型对照组比较差异有显著性意义(P<0.05)
**表示与模型对照组比较差异有极显著性意义(P<0.01)
从表2可见,各实验组大鼠总摄食量与模型对照组和正常对照组相比,没有太大的变化,因此均不具有显著性意义。
2.3本发明组合物对大鼠体内脂肪重量、脂/体比的影响
表3本发明组合物对大鼠脂肪重量、脂/体比的影响
*表示与模型对照组比较差异有显著性意义(P<0.05)
**表示与模型对照组比较差异有极显著性意义(P<0.01)
从表3可见,各实验组大鼠脂肪重量均低于模型对照组,实验组1与模型对照组的差异具有极显著意义(P<0.01),实验组2、3与模型对照组的差异具有显著意义(P<0.05),提示结果为阳性。各实验组大鼠脂/体比均低于模型对照组,且与模型对照组的差异具有显著性意义(P<0.05),提示结果为阳性。
本发明实施例4-13均按照上述方法进行了相似的试验,结果与上述结果相同。
3结论
大鼠经受试本发明组合物后,体重显著低于模型对照组,体内脂肪重量显著低于模型对照组,脂/体比显著低于模型对照组,且差异均具有显著性意义,表明本发明组合物具有减肥功能。
Claims (11)
1.一种具有减肥功能的组合物,其特征在于,由以下重量份配比的原料组成:青稞10-100份,荞麦10-100份,薏仁米10-100份,燕麦100-300份,带皮糜子10-100份、大豆粉100-300份、亚麻籽油微囊粉10-100份、浓缩乳清蛋白1-80份、大豆分离蛋白100-300份、低聚果糖1-100份、菊粉10-100份、赤藓糖醇10-200份、魔芋粉1-80份。
2.根据权利要求1所述的组合物,其特征在于,所述的原料重量份配比为:青稞20-80份,荞麦20-90份,薏仁米30-90份,燕麦30-80份,带皮糜子25-90份、大豆粉125-270份、亚麻籽油微囊粉25-90份、浓缩乳清蛋白5-65份、大豆分离蛋白125-280份、低聚果糖10-85份、菊粉20-80份、赤藓糖醇30-125份、魔芋粉5-65份。
3.根据权利要求2所述的组合物,其特征在于,所述的原料重量份配比为:青稞40-70份,荞麦40-80份,薏仁米40-80份,燕麦45-70份,带皮糜子45-80份、大豆粉165-225份、亚麻籽油微囊粉35-65份、浓缩乳清蛋白10-50份、大豆分离蛋白150-250份、低聚果糖20-60份、菊粉35-70份、赤藓糖醇65-115份、魔芋粉10-40份。
4.根据权利要求1所述的组合物,其特征在于,所述组合物为口服制剂,呈现为粉剂、片剂、胶囊剂、丸剂、颗粒剂、口服液体制剂、袋装茶剂、袋泡茶剂任意一种形式。
5.根据权利要求1所述的组合物,其特征在于,所述组合物是通过以下步骤制备而成:将所述重量份的原料粉碎成粗粉;或加水或不同浓度的乙醇提取,提取液浓缩干燥得粗提物;或进一步采用水提醇沉法、离心法、有机溶剂萃取法、柱层析法、水蒸气蒸馏法进行精制得到精提物;上述药材粗粉或粗提物或精提物不加或者加入适量辅料制成相应剂型。
6.根据权利要求5所述的组合物,其特征在于,所述组合物是通过以下步骤制备而成:
1)将青稞、荞麦、薏仁米、燕麦、带皮糜子炒制,粉碎、过筛,制得组合物A,将低聚果糖、菊粉、赤藓糖醇、魔芋粉粉碎过筛制得组合物B;
2)将组合物A、B与大豆粉、亚麻籽油微囊粉、浓缩乳清蛋白、大豆分离蛋白混合,加适量辅料,混合均匀,过筛,即得。
7.根据权利要求6所述的组合物,其特征在于,所述辅料为硬脂酸镁、滑石粉、微粉硅胶、二氧化硅、硬脂酸、单硬脂酸甘油酯、聚丙烯酰胺一种或几种。
8.一种制备权利要求1所述组合物的方法,其特征在于,所述方法包括以下步骤:将所述重量份的原料粉碎成粗粉;或加水或不同浓度的乙醇提取,提取液浓缩干燥得粗提物;或进一步采用水提醇沉法、离心法、有机溶剂萃取法、柱层析法、水蒸气蒸馏法进行精制得到精提物;上述药材粗粉或粗提物或精提物不加或者加入适量辅料制成相应剂型。
9.根据权利要求8所述的方法,其特征在于,所述方法包括以下步骤:
1)将青稞、荞麦、薏仁米、燕麦、带皮糜子炒制,粉碎、过筛,制得组合物A,将低聚果糖、菊粉、赤藓糖醇、魔芋粉粉碎过筛制得组合物B;
2)将组合物A、B与大豆粉、亚麻籽油微囊粉、浓缩乳清蛋白、大豆分离蛋白混合,加适量辅料,混合均匀,过筛,即得。
10.根据权利要求1-3任一项所述的组合物或权利要求8-9所述方法制备的组合物的用途,其特征在于,所述组合物在制备减肥的食品或保健品中的用途。
11.根据权利要求10所述的用途,其特征在于,所述组合物在制备供糖尿病人、肥胖性高血压病人和心血管病人食用的食品或保健品中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610896755.3A CN107951006A (zh) | 2016-10-14 | 2016-10-14 | 一种具有减肥功能的组合物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610896755.3A CN107951006A (zh) | 2016-10-14 | 2016-10-14 | 一种具有减肥功能的组合物及其制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107951006A true CN107951006A (zh) | 2018-04-24 |
Family
ID=61953611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610896755.3A Pending CN107951006A (zh) | 2016-10-14 | 2016-10-14 | 一种具有减肥功能的组合物及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107951006A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109007840A (zh) * | 2018-09-18 | 2018-12-18 | 广东雪芝康生物科技有限公司 | 一种通过调节基因减肥降血脂的植物营养粉及其制备方法 |
CN109363166A (zh) * | 2018-09-18 | 2019-02-22 | 丽睿客信息科技(北京)有限公司 | 一种用于调节女性身体健康平衡的组合物 |
CN109820202A (zh) * | 2019-04-03 | 2019-05-31 | 江西安顺堂生物科技有限公司 | 一种增肌、减肥代餐的制剂及制备工艺 |
CN113080375A (zh) * | 2021-05-07 | 2021-07-09 | 山西省农业科学院农产品加工研究所 | 一种高活性组分糜子营养棒及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102687750A (zh) * | 2012-06-13 | 2012-09-26 | 杭州诺伽特健康科技有限公司 | 一种减肥代餐蛋白型固体饮料 |
CN104287049A (zh) * | 2014-11-07 | 2015-01-21 | 江苏艾兰得营养品有限公司 | 一种体重管理的代餐蛋白质粉固体饮料 |
-
2016
- 2016-10-14 CN CN201610896755.3A patent/CN107951006A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102687750A (zh) * | 2012-06-13 | 2012-09-26 | 杭州诺伽特健康科技有限公司 | 一种减肥代餐蛋白型固体饮料 |
CN104287049A (zh) * | 2014-11-07 | 2015-01-21 | 江苏艾兰得营养品有限公司 | 一种体重管理的代餐蛋白质粉固体饮料 |
Non-Patent Citations (1)
Title |
---|
LELE: ""燕教授粗粮代餐粉让你健康瘦瘦身排毒润肠通便"", 《豆瓣》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109007840A (zh) * | 2018-09-18 | 2018-12-18 | 广东雪芝康生物科技有限公司 | 一种通过调节基因减肥降血脂的植物营养粉及其制备方法 |
CN109363166A (zh) * | 2018-09-18 | 2019-02-22 | 丽睿客信息科技(北京)有限公司 | 一种用于调节女性身体健康平衡的组合物 |
CN109820202A (zh) * | 2019-04-03 | 2019-05-31 | 江西安顺堂生物科技有限公司 | 一种增肌、减肥代餐的制剂及制备工艺 |
CN113080375A (zh) * | 2021-05-07 | 2021-07-09 | 山西省农业科学院农产品加工研究所 | 一种高活性组分糜子营养棒及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Khorshidian et al. | Fenugreek: potential applications as a functional food and nutraceutical | |
KR100645385B1 (ko) | 비만 억제용 조성물 | |
CN108112996A (zh) | 一种控制2型糖尿病人群高血糖和提高免疫力的营养组合物 | |
WO2005074962A1 (ja) | 筋張力増強剤 | |
CN102113648A (zh) | 一种适合“五高”代谢综合症人群的特膳面条及其制备方法 | |
CN101912090B (zh) | 辅助降血脂青稞保健粥及其制备方法 | |
JP2013010762A (ja) | 澱粉サブタイプおよび脂質代謝 | |
EP2355669A2 (en) | Dietary fiber compositions | |
CN108850913A (zh) | 一种含益生元糖尿病特殊医学用途配方食品及其制备方法 | |
CN107951006A (zh) | 一种具有减肥功能的组合物及其制备方法和用途 | |
CN108391785A (zh) | 一种功能性代餐粉及其制作工艺与应用 | |
CN102697057A (zh) | 一种具有减肥、排毒、降糖、降脂、降压功能的营养餐 | |
CN109007856A (zh) | 一种适合高血压、高血脂、高血糖和高尿酸人群服用的代餐粉及制备方法 | |
JP2022031912A (ja) | 経口組成物 | |
CN110574862A (zh) | 一种适用于青少年儿童的营养减肥代餐粉及其制备方法 | |
CN103404778A (zh) | 一种苦荞面 | |
CN103610144A (zh) | 一种降糖核桃粉及其制备方法 | |
KR20100109697A (ko) | 체중감량 및 고지혈증 개선 효과가 있는 기능성 조성물 | |
CN113018364A (zh) | 一种具有降血糖功能的组合物和饼干 | |
CN107259363A (zh) | 糖尿病人五谷代餐粉 | |
CN103053638A (zh) | 一种恢复胰岛功能消除胰岛素抵抗的面粉及其制法 | |
CN106974274A (zh) | 一种降三高食补剂 | |
CN107095297A (zh) | 一种营养保健食品 | |
CN107259318A (zh) | 一种营养保健食品 | |
CN108523142A (zh) | 一种用于调节糖尿病及肥胖症的主食代餐组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180424 |
|
RJ01 | Rejection of invention patent application after publication |